Intensity Therapeutics, Inc. has been granted a 180-day extension by Nasdaq to regain compliance with the minimum bid price requirement.
The Company now has until June 1, 2026, to meet the minimum bid price requirement set by Nasdaq.
The extension does not immediately impact the listing or trading of Intensity Therapeutics' shares on the Nasdaq Capital Market.
Compliance Extension
Intensity Therapeutics granted 180 days to meet Nasdaq's minimum bid price requirement.
Stock Trading Continues
Shares of Intensity Therapeutics will keep trading on the Nasdaq Capital Market under the symbol 'INTS' during the extension period.
Compliance Monitoring
The Company will actively monitor its stock's closing bid price to take necessary actions for compliance.
- Intensity Therapeutics' patented intratumoral cancer therapies show promising results in clinical trials.
- The ability of INT230-6 to kill tumors and trigger an immune response within days is a potential breakthrough in cancer treatment.
Intensity Therapeutics remains dedicated to regaining compliance with Nasdaq's rules and advancing its innovative cancer therapies.